{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:23:00Z","timestamp":1791559380300,"version":"4.3.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Doc Ophthalmol"],"DOI":"10.1007\/s10633-026-10146-2","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:43:56Z","timestamp":1788353036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Electronegative ERG revealing melanoma-associated retinopathy in a patient with trametinib-associated retinopathy"],"prefix":"10.1007","author":[{"given":"Masayuki","family":"Inuzuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyofumi","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Fujibayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Hisatomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"12","key":"10146_CR1","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1001\/archophthalmol.2009.311","volume":"127","author":"Y Lu","year":"2009","unstructured":"Lu Y, Jia L, He S et al (2009) Melanoma-associated retinopathy: a paraneoplastic autoimmune complication. Arch Ophthalmol 127(12):1572\u20131580. https:\/\/doi.org\/10.1001\/archophthalmol.2009.311","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10146_CR2","first-page":"211","volume":"110","author":"K Murayama","year":"2006","unstructured":"Murayama K, Takita H, Kiyohara Y et al (2006) Melanoma-associated retinopathy with unknown primary site in a Japanese woman. Nippon Ganka Gakkai Zasshi 110(3):211\u2013217","journal-title":"Nippon Ganka Gakkai Zasshi"},{"issue":"2","key":"10146_CR3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10384-013-0300-6","volume":"58","author":"Y Morita","year":"2014","unstructured":"Morita Y, Kimura K, Fujitsu Y et al (2014) Autoantibodies to transient receptor potential cation channel, subfamily M, member 1 in a Japanese patient with melanoma-associated retinopathy. Jpn J Ophthalmol 58(2):166\u2013171. https:\/\/doi.org\/10.1007\/s10384-013-0300-6","journal-title":"Jpn J Ophthalmol"},{"issue":"12","key":"10146_CR4","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1016\/j.ophtha.2013.07.037","volume":"120","author":"MD Dalal","year":"2013","unstructured":"Dalal MD, Morgans CW, Duvoisin RM et al (2013) Diagnosis of occult melanoma using transient receptor potential melastatin 1 (TRPM1) autoantibody testing: a novel approach. Ophthalmology 120(12):2560\u20132564. https:\/\/doi.org\/10.1016\/j.ophtha.2013.07.037","journal-title":"Ophthalmology"},{"key":"10146_CR5","doi-asserted-by":"publisher","first-page":"6607441","DOI":"10.1155\/2021\/6607441","volume":"2021","author":"Y Shinohara","year":"2021","unstructured":"Shinohara Y, Mukai R, Ueno S, Akiyama H (2021) Clinical findings of melanoma-associated retinopathy with anti-TRPM1 antibody. Case Rep Ophthalmol Med 2021:6607441. https:\/\/doi.org\/10.1155\/2021\/6607441","journal-title":"Case Rep Ophthalmol Med"},{"issue":"3","key":"10146_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10633-022-09901-y","volume":"145","author":"WC Hung","year":"2022","unstructured":"Hung WC, Cheng HC, Wang AG (2022) Melanoma-associated retinopathy with anti-TRPM1 autoantibodies showing concomitant off-bipolar cell dysfunction. Doc Ophthalmol 145(3):263\u2013270. https:\/\/doi.org\/10.1007\/s10633-022-09901-y","journal-title":"Doc Ophthalmol"},{"key":"10146_CR7","doi-asserted-by":"publisher","first-page":"102098","DOI":"10.1016\/j.ajoc.2024.102098","volume":"36","author":"DC Cohen","year":"2024","unstructured":"Cohen DC, Sumaroka A, Paulos JA et al (2024) Anti-TRPM1 autoantibody-positive unilateral melanoma associated retinopathy (MAR) triggered by immunotherapy recapitulates functional and structural details of TRPM1-associated congenital stationary night blindness. Am J Ophthalmol Case Rep 36:102098. https:\/\/doi.org\/10.1016\/j.ajoc.2024.102098","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"3","key":"10146_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10633-020-09772-1","volume":"141","author":"MS Kim","year":"2020","unstructured":"Kim MS, Hong HK, Ko YJ et al (2020) A case of melanoma-associated retinopathy with autoantibodies against TRPM1. Doc Ophthalmol 141(3):313\u2013318. https:\/\/doi.org\/10.1007\/s10633-020-09772-1","journal-title":"Doc Ophthalmol"},{"key":"10146_CR9","doi-asserted-by":"publisher","first-page":"1445180","DOI":"10.3389\/fmed.2024.1445180","volume":"11","author":"RM Mosavi-Hecht","year":"2024","unstructured":"Mosavi-Hecht RM, Yang P, Heyer B et al (2024) Case report: longitudinal evaluation and treatment of a melanoma-associated retinopathy patient. Front Med (Lausanne) 11:1445180. https:\/\/doi.org\/10.3389\/fmed.2024.1445180","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"10146_CR10","doi-asserted-by":"publisher","first-page":"e69506","DOI":"10.1371\/journal.pone.0069506","volume":"8","author":"WH Xiong","year":"2013","unstructured":"Xiong WH, Duvoisin RM, Adamus G et al (2013) Serum TRPM1 autoantibodies from melanoma associated retinopathy patients enter retinal on-bipolar cells and attenuate the electroretinogram in mice. PLoS ONE 8(8):e69506. https:\/\/doi.org\/10.1371\/journal.pone.0069506","journal-title":"PLoS ONE"},{"issue":"6","key":"10146_CR11","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1167\/iovs.19-26775","volume":"60","author":"RM Duvoisin","year":"2019","unstructured":"Duvoisin RM, Ren G, Haley TL, Taylor MH, Morgans CW (2019) TRPM1 autoantibodies in melanoma patients without self-reported visual symptoms. Invest Ophthalmol Vis Sci 60(6):2330\u20132335. https:\/\/doi.org\/10.1167\/iovs.19-26775","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10146_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10633-022-09872-0","volume":"144","author":"AG Robson","year":"2022","unstructured":"Robson AG, Frishman LJ, Grigg J et al (2022) ISCEV standard for full-field clinical electroretinography (2022 update). Doc Ophthalmol 144(3):165\u2013177. https:\/\/doi.org\/10.1007\/s10633-022-09872-0","journal-title":"Doc Ophthalmol"},{"issue":"12","key":"10146_CR13","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.ophtha.2017.05.038","volume":"124","author":"JH Francis","year":"2017","unstructured":"Francis JH, Habib LA, Abramson DH et al (2017) Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy. Ophthalmology 124(12):1788\u20131798. https:\/\/doi.org\/10.1016\/j.ophtha.2017.05.038","journal-title":"Ophthalmology"},{"key":"10146_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ejca.2016.06.018","volume":"65","author":"U Urner-Bloch","year":"2016","unstructured":"Urner-Bloch U, Urner M, Jaberg-Bentele N et al (2016) MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: long-term ophthalmic effects. Eur J Cancer 65:130\u2013138. https:\/\/doi.org\/10.1016\/j.ejca.2016.06.018","journal-title":"Eur J Cancer"},{"issue":"5","key":"10146_CR15","doi-asserted-by":"publisher","first-page":"e616","DOI":"10.1093\/oncolo\/oyae014","volume":"29","author":"KW Jeng-Miller","year":"2024","unstructured":"Jeng-Miller KW, Miller MA, Heier JS (2024) Ocular effects of MEK inhibitor therapy: literature review, clinical presentation, and best practices for mitigation. Oncologist 29(5):e616\u2013e621. https:\/\/doi.org\/10.1093\/oncolo\/oyae014","journal-title":"Oncologist"},{"issue":"2","key":"10146_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/ICB.0000000000000929","volume":"16","author":"M van Lint","year":"2022","unstructured":"van Lint M, Ebraert H, Van Aken EH (2022) Mitogen-activated protein inhibitors: full-field electroretinogram demonstrating generalized retinal dysfunction. Retin Cases Brief Rep 16(2):189\u2013193. https:\/\/doi.org\/10.1097\/ICB.0000000000000929","journal-title":"Retin Cases Brief Rep"},{"issue":"12","key":"10146_CR17","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1097\/IAE.0000000000002329","volume":"39","author":"S Ueno","year":"2019","unstructured":"Ueno S, Inooka D, Nakanishi A et al (2019) Clinical course of paraneoplastic retinopathy with anti-TRPM1 autoantibody in Japanese cohort. Retina 39(12):2410\u20132418. https:\/\/doi.org\/10.1097\/IAE.0000000000002329","journal-title":"Retina"}],"container-title":["Documenta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10633-026-10146-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10633-026-10146-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10633-026-10146-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:43:57Z","timestamp":1788353037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10633-026-10146-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":17,"alternative-id":["10146"],"URL":"https:\/\/doi.org\/10.1007\/s10633-026-10146-2","relation":{},"ISSN":["0012-4486","1573-2622"],"issn-type":[{"value":"0012-4486","type":"print"},{"value":"1573-2622","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"2 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This report adhered to the Declaration of Helsinki and institutional requirements.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication was obtained from the patient.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}